Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. (3rd September 2017)

• Record Type: Journal Article
• Authors: Gagliardini, Roberta; Fabbiani, Massimiliano; Colafigli, Manuela; D'Avino, Alessandro; Mondi, Annalisa; Borghetti, Alberto; Lamonica, Silvia; Cauda, Roberto; De Luca, Andrea; Di Giambenedetto, Simona
• Is Part Of: Journal of chemotherapy. Volume 29:Number 5(2017)
• Page Start: 299
• Page End: 307
• Publication Date: 2017-09-03
• Subjects: HAART -- Cholesterol -- Dyslipidemia -- Cardiovascular risk -- Framingham risk score -- DAD risk score; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2016.1269040
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Tenofovir could have a direct lipid-lowering effect. The aim of our retrospective study was to investigate changes in cardiovascular risk after switching from a tenofovir-sparing to a tenofovir-containing backbone. Lipid parameters and cardiovascular risk [calculated using 10-years Framingham Risk Score (FRS) and 5-years DAD Risk Score (DRS)] were analysed at baseline and after three months. 273 patients were enrolled. After switching, significant decreases in total cholesterol (TC) (–8.2mg/dl, p < 0.001), LDL (–8.7mg/dl, p < 0.001) and DRS (mean –0.26%, p < 0.001) were observed, while a reduction in FRS was only observed in patients with pre-switch high TC or medium-high (>10%) FRS. Pre-switch factors associated with DRS reduction were higher TC, abacavir, new generation protease inhibitors, while zidovudine predicted an increase of DRS. Our results suggest that the improvement of lipid parameters observed after switching to a tenofovir-containing backbone could lead to a significant reduction in predicted cardiovascular risk, which became more evident in subjects with higher cardiovascular risk.